My 10 cents worth. I am not a statistician. Whilst the prochymal phase 3 trial did not meet its primary end goals there seems to have been significant data suggesting positive responses nonetheless particularly in children. Apparently there were 10% more of the most seriously affected in the prochymal group compared to the control and other design faults that could be improved on. No doubt useful information was learnt for the design of another trial (at least I hope SI thinks so)
Cell Therapy News/Articles, page-48
-
- There are more pages in this discussion • 17,733 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |